Quantcast

Latest emphysema Stories

2008-11-11 09:00:47

Kamada, a biopharmaceutical company, has signed a long-term supply agreement with a multi-national company for the raw material required to manufacture alpha-1-antitrypsin, the company's flagship product, which is administered intravenously or by inhalation. This agreement guarantees Kamada a steady supply of raw material that meets the international standards set by the FDA and European Medicines Agency. The suppliers are also required to meet the highest standards of production and...

2008-10-29 15:00:27

PHILADELPHIA, Oct. 29 /PRNewswire-USNewswire/ -- Data from a Phase IIIb clinical trial demonstrate that Perforomist(TM) (formoterol fumarate) Inhalation Solution nebulized treatment provided prolonged bronchodilation and increased patient satisfaction compared to albuterol/ipratropium by metered-dose inhaler (MDI). These data were presented today in Philadelphia at CHEST 2008, the annual scientific assembly of the American College of Chest Physicians (ACCP). Perforomist(TM) Solution was...

2008-10-29 15:00:10

PHILADELPHIA, Oct. 29 /PRNewswire-FirstCall/ -- GlaxoSmithKline announced today that data from a three-year study of patients with Chronic Obstructive Pulmonary Disease (COPD) found that the inhaled corticosteroid in Advair Diskus 250/50, fluticasone propionate, did not show an adverse effect on bone mineral density (BMD) measured at the lumbar spine and total hip compared to salmeterol alone. In this study, designed to show equivalent rate of change in BMD for Advair and salmeterol,...

2008-10-28 15:00:11

PHILADELPHIA, Oct. 28 /PRNewswire-FirstCall/ -- GlaxoSmithKline today announced findings from a cross-sectional study which showed that 26 percent of primary care patients 40 years of age and older with a history of smoking and symptoms of chronic bronchitis actually had airway obstruction consistent with chronic obstructive pulmonary disease (COPD) - yet were not diagnosed with the disease. The data also show that as age and smoking history increased the percent of patients with COPD...

2008-10-27 12:00:29

U.S. scientists are studying an investigational emphysema treatment that involves using stents to create new pathways for air in diseased lungs. Researchers at the National Jewish Medical and Research Center said the new procedure involves creating openings in the airway wall connecting the damaged lung tissue to the natural airway in a minimally invasive procedure. The holes, kept open by small stents, could relieve the hyperinflation of the lungs, allowing the healthy parts of the lungs...

2008-10-27 12:00:29

Spiration, a developer of medical devices designed to benefit patients with acute and chronic conditions of the lung, has received humanitarian device exemption approval from the FDA for the use of its minimally invasive IBV Valve System to control prolonged air leaks of the lung, or significant air leaks that are likely to become prolonged, following lobectomy, segmentectomy, or lung volume reduction surgery. This FDA approval represents the first for a bronchial valve implant for the...

2008-10-27 09:00:42

Franklin Square Hospital Center announces the start of the EASE (Exhale Airway Stents for Emphysema) Trial to explore an investigational treatment for advanced widespread emphysema/COPD. The trial focuses on airway bypass, a bronchoscopic procedure designed to reduce lung hyperinflation and shortness of breath (the clinical hallmarks of emphysema/COPD) by making new pathways for trapped air to exit the lungs. During the airway bypass procedure, new openings are created in the airway wall...

2008-10-24 18:00:43

Spiration, Inc., a developer of novel medical devices designed to benefit patients with acute and chronic conditions of the lung, announced today that the company has received Humanitarian Device Exemption (HDE) approval from the U.S. Food and Drug Administration (FDA) for the use of its minimally invasive IBV(R) Valve System to control prolonged air leaks of the lung, or significant air leaks that are likely to become prolonged, following lobectomy, segmentectomy, or lung volume reduction...

2008-10-22 12:00:51

Researchers at National Jewish Health are testing an investigational treatment to learn if poking holes in the lungs of emphysema patients can immediately help them breathe more easily. Destruction of lung tissue caused by emphysema can leave lungs stiff and overinflated with air that cannot escape. The holes, kept open by small stents inserted during a minimally invasive procedure, could relieve the hyperinflation of the lungs, allowing the healthy parts of the lungs to more easily inflate...

2008-10-21 09:00:54

Patients in the Valley with emphysema might soon be breathing a little easier thanks to a new airway bypass study called the Exhale Airways Stents for Emphysema (EASE) trial. The trial principal is Dr. Karl Van Gundy aided by investigators Drs. Michael Peterson, Jose Joseph, Timothy Evans and Kathryn Bilello -- all pulmonologists at UCSF Fresno Medical Education Program. The study is a multi-center, international trial that is designed to evaluate the safety and effectiveness of this new and...


Latest emphysema Reference Libraries

Lung
2013-01-01 15:53:59

The lung is a vital organ that is a part of the respiratory system. Generally a person has two lungs; however, the body can function with only one. The lung’s main function is to move oxygen and carbon dioxide into and out of the bloodstream through gas exchange. The lungs are located lateral to the heart in the thoracic cavity. Each lung has a tip called the apex, which is superior in the body. The bases of the lungs rest on the diaphragm. They appear to be spongy due to their bundles of...

More Articles (1 articles) »
Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related